Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Goldman Sachs analyst expects positive updates from Vertex's first Investor Day as a public company on March 19, reiterates ...

The latest trading session saw Vertex Pharmaceuticals (VRTX) ending at $503.20, denoting a -1.37% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Nvidia (NVDA) CEO Jensen Huang took to the stage Tuesday afternoon to deliver his keynote speech at the chip giant's 2025 GTC event (GPU Technology Conference), where he previewed the company's ...

This algorithm has quadratic run time so it can be slow with very large profiles ... with many edges meeting at each polygon vertex. The result is an alternation of flat triangular faces with conical ...